TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BellRing Brands ( (BRBR) ) just unveiled an announcement.
On November 19, 2025, BellRing Brands, Inc. announced the approval of a new $600 million share repurchase authorization, effective immediately, while canceling its previous $400 million authorization. The new authorization, which spans two years, allows for flexible repurchase methods and does not obligate the company to buy a specific amount of shares. The decision reflects BellRing’s strategic financial management, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (BRBR) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on BellRing Brands stock, see the BRBR Stock Forecast page.
Spark’s Take on BRBR Stock
According to Spark, TipRanks’ AI Analyst, BRBR is a Neutral.
BellRing Brands’ strong cash flow and earnings performance are offset by financial instability and bearish technical indicators. The company’s moderate valuation and challenges in the competitive landscape further temper the overall score.
To see Spark’s full report on BRBR stock, click here.
More about BellRing Brands
BellRing Brands, Inc. (NYSE: BRBR) is a dynamic and fast-growing consumer brands business focused on the convenient nutrition category. Its key brands include Premier Protein, the leading ready-to-drink protein and convenient nutrition brand, and Dymatize, known for the top hydrolyzed protein powder. BellRing Brands distributes its products across over 90 countries through various channels including club, mass, food, eCommerce, specialty, drug, and convenience.
Average Trading Volume: 3,365,671
Technical Sentiment Signal: Sell
Current Market Cap: $3.5B
For a thorough assessment of BRBR stock, go to TipRanks’ Stock Analysis page.